相关实验视频

Updated: Jun 12, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

通过eIF4G1重新编程免疫抑制的微环境,以消除胰腺管道腺癌为目标

Lihong He¹, Xiaozhen Zhang¹, Fukang Shi²

¹Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China; MOE Joint International Research Laboratory of Pancreatic Diseases, Hangzhou, Zhejiang, China.

Cell reports. Medicine

|September 20, 2024

概括

向真核细胞启动因子4G1 (eIF4G1) 在胰腺癌中显示出有前途. 抑制eIF4G1限制了瘤生长,并改善了生存率,尤其是在现有疗法下.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
免疫学免疫学免疫学

背景情况:

胰腺管腺癌 (PDAC) 治疗受到瘤异质性和免疫抑制微环境的限制.
细胞启动因子 (eIF) 4F复合体调节翻译和癌症信号传递.
eIF4F的一个子单元eIF4G1在PDAC中过度表达,并与预后不佳有关.

研究的目的:

研究eIF4G1在PDAC进展中的作用及其作为治疗点的潜力.
在PDAC模型中评估eIF4G1抑制单独和与其他治疗结合的疗效.

主要方法:

在PDAC患者样本和小鼠模型中评估eIF4G1表达.
在PDAC小鼠模型中抑制了eIF4G1.
结合eIF4G1抑制与PD1/PDL1抗剂和凝胺.
分析了对细胞因子/化学因子产生,T细胞化学反应,整体β1转化和FAK-ERK/AKT信号传递的下游影响.

主要成果:

eIF4G1过度表达与PDAC患者的预后不佳相关.
在PDAC小鼠中,eIF4G1抑制限制了瘤进展和延长了生存时间.
组合疗法 (eIF4G1抑制+PD1/PDL1抗剂+凝) 显示出增强的疗效.
抑制eIF4G1降低了亲纤维细胞因子/化学因子,并改善了T细胞透.
eIF4G1抑制导致整体蛋白β1转化受损,并影响了FAK-ERK/AKT通路.

结论:

eIF4G1在PDAC进展和免疫逃避中发挥着重要作用.
针对eIF4G1是一个有希望的治疗策略,用于PDAC.
涉及eIF4G1抑制的组合疗法可以克服治疗耐药性.

关键词:

eIF4G1 是一个国际投资基金免疫疗法免疫疗法整体中的β1β1 翻译法规翻译法规瘤纤维化瘤纤维化瘤微环境是一个微环境.

更多相关视频

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation

A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation

Published on: June 8, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...